TB-500 is a prescription therapy used for recovery and tissue support.

Patients seeking support for recovery and tissue support may qualify after evaluation by a licensed provider.

Yes. TB-500 is a compounded prescription peptide requiring a valid prescription from a licensed healthcare provider. A telehealth consultation, written informed consent, and full medical intake are required before dispensing to confirm clinical suitability and establish an individualized protocol for dose, frequency, and cycle length.

TB-500 is generally well tolerated at prescribed therapeutic doses. Common side effects may include injection site reactions such as transient redness, mild swelling, or brief discomfort at the administration site. Headache, mild nausea, or temporary fatigue have been reported during the initial treatment period. As with any peptide therapy, individual responses vary. Report any unusual, persistent, or worsening symptoms to your provider promptly.

TB-500 is not appropriate for patients who are pregnant or breastfeeding, as safety data in these populations is absent. Patients with a personal history of any malignancy require thorough provider and oncological evaluation before initiating therapy, as Thymosin Beta-4's angiogenic activity warrants caution in the context of tumor vascularization. Those with active autoimmune conditions or on immunosuppressive therapy require individualized provider review. TB-500 has not been studied in patients under 18 and is not indicated in this population.

Formal drug interaction studies for TB-500 have not been conducted. Based on its mechanism — which includes angiogenic activity and immune modulation — patients on anticoagulants or antiplatelet agents should discuss concomitant use with their provider, as additive vascular effects are theoretically possible. Patients on immunosuppressive medications should also discuss use with their provider, as TB-500's immune-modulatory properties may interact with those agents. Always provide a complete medication list before beginning treatment.

Patients with a history of malignancy must not use TB-500 without thorough oncological and provider evaluation. Those with cardiovascular conditions, autoimmune disease, or significant renal or hepatic impairment require individualized assessment before starting. Your provider requires a complete medical history and will determine whether TB-500 is appropriate given your clinical history, current health status, and treatment goals.